Aiming to find cancer at the first appointment.
We are developing a test that reads a drop of serum in about 90 seconds, with photonics and machine learning, designed to give the clinician a result during the appointment.
We are working with:
- 90 secs from a drop to a score on the reader
- 1 drop of serum, one single-use cartridge
- 4 in 5 cystoscopies today find no cancer
- 2,600+ human samples in our biobank
The problem
Imagine the answer at that first appointment.
Blood in the urine, or a PSA result in the grey zone, starts a long referral pathway: weeks or months of waiting, then a camera or a needle. Most of those procedures find no cancer. Serox aims to give clinicians more information at that first appointment, before the referral.
- 01
Prioritise who needs the camera
Four in five cystoscopies find no cancer. We are studying whether a blood test at the first appointment can help clinicians decide who needs one first.
- 02
More information in the grey zone
Ambiguous PSA results feed the MRI queue, and many biopsies find no cancer. We are studying whether Serox, run on the same blood draw, can add information before MRI or biopsy.
- 03
Free up the pathway
If the test performs as we hope, fewer unnecessary scopes, scans and biopsies would mean shorter queues for the patients who need them, at lower cost to the health system.
Serox Limited
A working prototype: drop to score on real hardware.
One instrument, built for many cancers. The same reader and cartridge are designed to run each new test. What changes is the model, and each model needs its own clinical evidence.
- 01
The whole fingerprint
Not a single-biomarker test: the spectrum captures a broad molecular fingerprint of the drop, so each new cancer is a new model, not a new chemistry.
- 02
The clinician picks the question
One cartridge per test, run for the question the clinician needs answered. Bladder cancer is our first target, then prostate.
- 03
Built on real samples
Our models are built and tested on more than 2,600 human samples held in our own biobank.
Raman is century-old physics. What changed: the hardware got cheap, and machine learning can read it.
Towards an answer at the first appointment.
Come and see it for yourself. Investors, clinicians and partners: we will show you the prototype working, from drop to score. Demonstrations are for information only: the test is not available for sale or clinical use.
